Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, announces the completion of cohort 2a in the clinical Phase I trial evaluating the drug candidate 177Lu-AKIR001. Cohort 2a investigated a higher activity dose than the run-in cohort. The results aligned with earlier findings, demonstrating continued favorable safety and encouraging tumor uptake. The trial is…
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, announces that data on its CD44v6-targeted radiotherapeutic candidate AKIR001 have been published in The Journal of Nuclear Medicine, one of the leading journals in nuclear medicine. The publication summarizes key studies underpinning the ongoing first-in-human Phase 1 trial at Karolinska University Hospital. It reports high…
What drives a cancer researcher to start a biotech company? In a newly published feature in Onkologi i Sverige, our CEO and co-founder, Professor Marika Nestor, shares insights from her journey through academia, innovation, and translational cancer research. The article traces her early steps into science, the growth of her all-female research group in Uppsala,…
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, will contribute to several academic presentations at the EANM Congress 2025 in Barcelona, October 4–8. Two have been selected as Top Rated Oral Presentations, highlighting continued development of the CD44v6-targeting antibody used in the company’s clinical-stage radiopharmaceutical—currently being investigated in a Phase I clinical trial….
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, announces the completion of the first cohort in the clinical Phase I trial evaluating the drug candidate 177Lu-AKIR001. No safety signals have been observed, and the trial is now proceeding to the next stage as planned. The trial is being conducted at Karolinska University Hospital,…
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, today announces that the first patient has been enrolled in the Phase 1 clinical trial of its drug candidate 177Lu-AKIR001. The trial is being conducted at Karolinska University Hospital, which also acts as the study sponsor, and marks an important milestone in Akiram’s efforts to…
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, today announces the launch of PRE-CISE, a Eurostars-funded research collaboration with Danish PreTT and TetraKit Technologies. The aim of the project is to develop a new generation of targeted alpha-therapeutics by expanding Akiram’s proprietary CD44v6-targeting antibody platform using advanced pre-targeting strategies and radiolabeling chemistry. The…
Our CEO, Professor Marika Nestor discusses advancing cancer treatment through radioimmunotherapy in a new interview ahead of her presentation at Antibody Engineering & Therapeutics. The interview highlights Akiram’s recent milestone: the approval of a Phase 1 clinical trial for 177Lu-AKIR001, a novel radiolabeled antibody targeting cancers with high CD44v6 expression, including head and neck squamous…
Akiram Therapeutics, a Swedish biotech company specializing in molecular radiation therapy, announces that the Swedish Medical Products Agency has approved the initiation of a Phase 1 clinical trial for its drug candidate 177Lu-AKIR001. This marks a key milestone in the company’s development of a pioneering cancer treatment aimed at offering new hope for patients with…
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, will participate in the European Association of Nuclear Medicine (EANM) Congress 2024 in Hamburg, from October 19-23. At this year’s congress, research findings on Akiram’s drug candidate AKIR001, resulting from several successful academic collaborations, will be presented. Akiram Therapeutics has developed 177Lu-AKIR001, a new type…